Once-sky-high stocks of pharmaceutical companies pursuing treatments for NASH have gotten a lot cheaper, especially this one. Last year's clinical trial was a phase 2 study of VK2809, an orally ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback